SLDB (Solid Biosciences) Tariff Resilience Score: 7/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLDB Solid Biosciences Inc SLDB
34 GF Score
Price $9.07
! 2 Warning Signs
View Full Analysis

What is Solid Biosciences Tariff Resilience Score?

Solid Biosciences SLDB +2.26% 34 Tariff Resilience Score is 7 as of Aug. 13, 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,362 Biotechnology companies, Solid Biosciences ranks better than 90.31% on this metric.

Solid Biosciences has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Solid Biosciences has Biotech industry generally less affected by tariffs. Global supply chain for research and development, but sales are less tariff-sensitive. Historical resilience due to niche market focus.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Solid Biosciences might have Highly Resilient.

Solid Biosciences  (NAS:SLDB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Solid Biosciences Tariff Resilience Score Related Terms

SLDB vs MNPR, DSGN, CLYM: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Solid Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Tariff Resilience Score falls into.


SLDB
34GF Score
Solid Biosciences Inc SLDB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Solid Biosciences (SLDB) has a Tariff Resilience Score of 7 as of Aug. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Solid Biosciences ranks #132 out of 1362 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Solid Biosciences' Tariff Resilience Score too high?
Solid Biosciences' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Solid Biosciences' value of 7 is 75% above this industry median. Based on the distribution chart, Solid Biosciences ranks #132 out of 1362 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Tariff Resilience Score compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #132 out of 1362 companies for Tariff Resilience Score. This places Solid Biosciences in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Solid Biosciences' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solid Biosciences's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Tariff Resilience Score is 7 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solid Biosciences Business Description

Address 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score

Get the complete analysis for SLDB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.07
Price